

Supplemental Table 1. Time trends in *A. baumannii* resistance

Pneumonia	2003-2005		2006-
	N	%	N
	Amikacin	2,776	26.81%
Tobramycin	4,592	39.69%	4,379
Aminoglycoside	2,872	23.95%	3,426
Doxycycline	36	41.38%	6
Minocycline	700	58.09%	276
Tetracyclines	726	58.08%	282
Doripenem	NR	NR	7
Imipenem	2,741	23.23%	4,294
Meropenem	2,304	39.30%	2,431
Carbapenem	2,764	22.37%	4,421
Ampicillin/Sulbactam	3,083	37.23%	3,650
Colistin	NR	NR	16
Polymyxin B	6	8.00%	86
Polymyxin	6	8.00%	101
Trimethoprim/Sulfamethoxazole	5,948	55.07%	5,675
MDR*	2,946	22.82%	4,064
Carbapenem + Aminoglycoside	1,097	9.44%	2,294
Aminoglycoside + Amp/Sulbactam	1,099	13.85%	1,972
Aminoglycoside + Minocycline	433	36.39%	153
Carbapenem + Amp/Sulbactam	1,113	13.80%	2,347
BSI	2003-2005		2006-
	N	%	N
Amikacin	489	18.85%	466
Tobramycin	805	27.01%	593
Aminoglycoside	521	16.83%	475
Doxycycline	27	31.40%	5
Minocycline	84	45.90%	54
Tetracyclines	111	42.53%	59
Doripenem	NR	NR	0
Imipenem	472	16.11%	579
Meropenem	2,304	39.30%	2,431
Carbapenem	490	15.63%	616
Ampicillin/Sulbactam	626	27.91%	579
Colistin	NR	NR	6
Polymyxin B	2	6.67%	16
Polymyxin	2	6.67%	22
Trimethoprim/Sulfamethoxazole	1,213	42.71%	912
MDR*	526	15.75%	538
Carbapenem + Aminoglycoside	209	7.03%	331
Aminoglycoside + Amp/Sulbactam	209	9.62%	287
Aminoglycoside + Minocycline	51	30.18%	30
Carbapenem + Amp/Sulbactam	236	10.90%	338

BSI = blood stream infection

*MDR = multidrug resistant, defined as non-susceptible to ≥ 1 drug in ≥ 3 class

Prevalence stratified by the source of infection

-2008	2009-2012	
%	N	%
37.30%	2,502	47.81%
44.94%	2,670	41.06%
32.73%	2,604	36.50%
60.00%	8	40.00%
36.56%	122	31.94%
36.86%	128	32.32%
87.50%	11	91.67%
42.94%	2,980	54.10%
52.41%	1,984	49.18%
41.46%	3,597	49.88%
48.10%	2,306	43.01%
2.45%	82	7.36%
12.59%	20	7.14%
7.63%	89	7.19%
60.03%	3,899	60.10%
36.27%	2,867	36.97%
22.69%	2,072	30.50%
26.94%	1,302	25.21%
21.22%	95	25.61%
31.86%	1,881	36.94%

-2008	2009-2012	
%	N	%
24.84%	372	35.13%
27.80%	426	30.45%
20.72%	407	26.64%
17.86%	3	25.00%
36.73%	37	26.43%
33.71%	40	26.67%
0.00%	10	100.00%
27.65%	473	40.32%
52.41%	1,984	49.18%
26.64%	609	38.86%
31.73%	353	32.12%
4.65%	8	4.23%
14.16%	1	2.44%
9.17%	9	4.21%
43.80%	624	45.58%
22.09%	454	27.07%
14.89%	345	23.60%
16.34%	202	19.52%
22.22%	28	21.21%
19.00%	302	28.73%

ies

Supplemental Table 2. Resistance among *A. baumannii* by US

	East North Central		East Sout
	N	%	N
Amikacin	2,391	43.54%	151
Tobramycin	2,755	49.69%	277
Aminoglycoside	2,218	35.73%	147
Doxycycline	40	31.25%	6
Minocycline	3	21.43%	3
Tetracyclines	43	30.28%	3
Doripenem	8	80.00%	
Imipenem	2,538	48.00%	68
Meropenem	1,063	40.34%	77
Carbapenem	2,832	45.01%	87
Ampicillin/Sulbactam	2,180	42.26%	210
Colistin	42	5.66%	0
Polymyxin B	5	9.62%	0
Polymyxin	47	5.92%	0
Trimethoprim/Sulfamethoxazole	4,184	69.91%	500
MDR*	2,634	39.34%	144
Carbapenem + Aminoglycoside	1,733	29.17%	35
Aminoglycoside + Amp/Sulbactam	1,116	22.98%	49
Aminoglycosie + Minocycline	3	21.43%	0
Carbapenem + Amp/Sulbactam	1,603	31.89%	36

*MDR = multidrug resistant, defined as non-susceptible to ≥ 1 drug in ≥ 3 classes

census divisions

h Central	Mid-Atlantic		Mountain		New E
%	N	%	N	%	N
17.24%	1,487	33.67%	1,120	55.36%	85
31.05%	1,776	34.59%	1,601	70.10%	120
15.52%	1,469	25.75%	1,201	50.38%	90
13.33%	0	0.00%			
6.25%	3	25.00%	331	52.62%	0
6.25%	3	23.08%	331	52.62%	0
8.65%	2,075	36.81%	903	38.38%	174
13.77%	1,683	55.23%	655	64.47%	30
9.02%	2,132	36.43%	861	36.44%	195
29.79%	2,032	39.07%	839	54.06%	182
0.00%	2	1.32%	2	0.97%	2
0.00%	10	2.60%	0	0.00%	94
0.00%	11	2.06%	2	0.93%	96
51.12%	3,041	54.41%	1,598	74.46%	324
14.31%	1,998	31.89%	1,240	50.39%	92
3.71%	927	17.18%	527	22.45%	45
7.06%	981	19.46%	560	35.43%	42
0.00%	0	0.00%	182	29.98%	0
5.11%	1,066	21.56%	393	25.69%	84

England	Pacific		South Atlantic		West North
%	N	%	N	%	N
8.53%	1,465	30.67%	1,979	27.67%	297
13.22%	1,772	32.48%	3,119	35.85%	549
7.87%	1,512	27.42%	2,049	22.67%	355
	27	52.94%	3	60.00%	0
0.00%	839	44.72%	38	46.91%	1
0.00%	863	44.95%	40	47.06%	1
	2	100.00%	15	93.75%	1
16.60%	1,370	26.10%	2,968	35.91%	625
20.69%	975	32.74%	2,080	49.22%	229
17.18%	1,446	25.12%	3,120	34.57%	659
26.88%	1,061	40.87%	2,445	36.80%	664
3.70%	25	6.70%	16	14.95%	2
25.82%			19	6.93%	
23.41%	25	6.70%	26	8.15%	2
28.75%	1,682	48.51%	4,425	53.53%	879
8.01%	1,083	18.17%	2,557	26.98%	599
3.97%	698	12.91%	1,336	15.34%	243
6.21%	488	19.52%	1,003	15.65%	222
0.00%	549	29.58%	17	22.37%	0
12.54%	555	22.33%	1,362	21.18%	492

ch Central	West South Central	
%	N	%
21.44%	1,004	32.95%
27.87%	1,496	43.50%
17.95%	1,264	35.18%
0.00%	9	90.00%
25.00%	55	37.93%
25.00%	62	40.52%
100.00%	2	100.00%
36.74%	818	25.77%
33.68%	944	37.96%
34.56%	1,165	29.50%
42.19%	984	42.95%
5.71%	21	5.06%
	3	2.56%
5.71%	20	4.77%
42.88%	1,638	47.87%
28.65%	1,048	24.88%
13.04%	804	23.32%
14.29%	610	28.80%
0.00%	39	37.86%
32.11%	626	28.55%